R&D investments of listed pharmaceutical companies remain unchanged

Published: 2015-11-20 15:52:56

Updated: 2015-11-20 15:53:04

R&D investments of listed pharmaceutical companies have remained unchanged.

According to the analysis result of 3^rd quarter’s performance reports of KOSPI and KOSDAQ listed pharmaceutical companies in 2015, the ratio of R&D investments to sales was 8.1%.

Although the ratio to sales was narrowly increased to 8.2% in 2014 from 7.8% in 2013, they invested the same ratio of investments compared w...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.